Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ ORP2 Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA583538
Description
Immunogen sequence: MNGEEEFFDA VTGFDSDNSS GEFSEANQKV TGMIDLDTSK NNRIGKTGER PSQENGIQKH RT.
This gene encodes a member of the oxysterol-binding protein (OSBP) family, a group of intracellular lipid receptors. Most members contain an N-terminal pleckstrin homology domain and a highly conserved C-terminal OSBP-like sterol-binding domain, although some members contain only the sterol-binding domain. This encoded protein contains only the sterol-binding domain. In vitro studies have shown that the encoded protein can bind strongly to phosphatic acid and weakly to phosphatidylinositol 3-phosphate, but cannot bind to 25-hydroxycholesterol. The protein associates with the Golgi apparatus. Transcript variants encoding different isoforms have been described.
Specifications
ORP2 | |
Polyclonal | |
Unconjugated | |
OSBPL2 | |
C130070J12Rik; DFNA67; DNFA67; FLJ20223; KIAA0772; MGC4307; MGC8342; mKIAA0772; ORP2; ORP-2; Osbpl2; OSBP-related protein 2; oxysterol binding protein like 2; oxysterol binding protein-like 2; oxysterol-binding protein-like 2; oxysterol-binding protein-related protein 2; RP11-157P1.2 | |
Rabbit | |
Antigen Affinity Chromatography | |
RUO | |
9885 | |
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
Liquid |
Immunohistochemistry (Paraffin), Western Blot, Immunocytochemistry, Western Blot | |
0.2 mg/mL | |
PBS with 40% glycerol and 0.02% sodium azide; pH 7.2 | |
Q9H1P3 | |
OSBPL2 | |
Recombinant protein corresponding to Human OSBPL2. Recombinant protein control fragment (Product #RP-99419). | |
100 μL | |
Primary | |
Human | |
Antibody | |
IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction